Cognitive Stimulation Program (PEC): Our Experience from January 2018 to March 2020
Antonella Mellino1, Maria Paz Rodriguez2 and Cristian Flavio Isaac3*
1Cognitive Psychologist Secretary of Health of Almirante Brown, Foundation H. A. Barceló, Argentina
2Psychologist Secretary of Health of Almirante Brown, Foundation H. A. Barceló, Argentina
3Neurologist Medical Secretary of Health of Admiral Brown, Foundation H. A. Barceló, Argentina
*Corresponding Author: Cristian Flavio Isaac, Cognitive Psychologist Secretary of Health of Almirante Brown, Foundation H. A. Barceló, Buenos Aires Province, Argentina.
Received: February 01, 2022 Published: February 18, 2022
Abstract
The PEC is a program that began in January 2018 in the CAPS of Alte Brown, Province of Bs As, Argentina due to the demand in the CAPS for pathological forgetfulness. Cognitive impairment and neurodegenerative diseases are currently prevalent pathologies because our population lives longer due to advances in medicine. In our work we achieved the following results: age 51 to 80 years old (72%); female sex: 133 (64.5%); evolution time of pathological forgetfulness: 136 (66%); Risk factors that affect the transition from normal aging to MCI are: 1. CRC 5 – 7: 170 (82.5%), 2. Homocysteine : 33 (16%), 3. Cerebrovascular disease: 29 (14%) , 4. Polypharmacy: 132 (64%), 5. Hypercholesterolemia: 48 (23.2%). 6. Head Injury: 27 (13.1%), 7. Hypertension: 102 (49.5%), 8. Risk of Cardiovascular Disease: 20 (9.7%), 9. Depression: 35 (16.9 %); The risk factors for conversion from MCI to dementia are: 1. Diabetes: 91 (44.1%), 2. Neuropsychiatric symptoms : 35 (16.9%), 3. Metabolic syndrome: 139 (67.4%), 4. Folate deficiencies: 36 (17.4%); vitamin D: 66 (32%); psychoactive drugs: 75 patients ( clonazepam : 34 (16.5%); alprazolam : 13 (6.3%)); Neurocognitive test : DCAMD: 179 (86.8%)
Keywords: Cognitive Stimulation Program (PEC), Neurocognitive, Dementia
Citation: Mellino A, Rodriguez MP, Isaac CF. “Cognitive Stimulation Program (PEC): Our Experience from January 2018 to March 2020”. SVOA Neurology 3:1 (2022) Pages 21-26.
